Comparative Pharmacology
Head-to-head clinical analysis: DEXTROAMPHETAMINE SULFATE versus PEMOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROAMPHETAMINE SULFATE versus PEMOLINE.
DEXTROAMPHETAMINE SULFATE vs PEMOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases extracellular levels of norepinephrine and dopamine by blocking reuptake and promoting release from presynaptic terminals, via trace amine-associated receptor 1 (TAAR1) agonism and vesicular monoamine transporter 2 (VMAT2) inhibition.
Pemoline is a central nervous system stimulant that enhances dopaminergic and noradrenergic transmission by blocking the reuptake of dopamine and norepinephrine at the synaptic cleft. It also has mild monoamine oxidase inhibitory activity.
5-60 mg/day orally divided every 4-6 hours, starting at 5 mg once or twice daily.
Oral, 37.5 mg once daily in the morning; may increase by 18.75 mg weekly to a maximum of 112.5 mg/day (divided into 2 doses if total dose > 75 mg).
None Documented
None Documented
9-11 hours (adults); clinical context: twice-daily dosing achieves steady-state in ~2-3 days.
Terminal elimination half-life is 8-12 hours in children; 12-16 hours in adults. Steady-state is reached within 2-3 days.
Primarily renal (30-50% unchanged at acidic pH, less at alkaline pH); ~50% as metabolites (mostly deaminated and hydroxylated); minimal biliary/fecal.
Pemoline is primarily excreted renally as unchanged drug (40-50%) and metabolites; approximately 20-30% is excreted in feces via biliary elimination.
Category D/X
Category C
CNS Stimulant
CNS Stimulant